ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AUPH Aurinia Pharmaceuticals Inc

4.8304
-0.1996 (-3.97%)
Apr 25 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,540,488
Bid Price 4.85
Ask Price 4.91
News -
Day High 5.01

Low
4.71

52 Week Range

High
12.43

Day Low 4.77
Company Name Stock Ticker Symbol Market Type
Aurinia Pharmaceuticals Inc AUPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.1996 -3.97% 4.8304 19:20:11
Open Price Low Price High Price Close Price Prev Close
4.96 4.77 5.01 4.87 5.03
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,887 1,540,488 $ 4.83 $ 7,446,420 - 4.71 - 12.43
Last Trade Time Type Quantity Stock Price Currency
17:24:44 formt 10,000 $ 4.8304 USD

Aurinia Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
702.84M 144.62M - 175.51M -78.02M -0.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aurinia Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AUPH Message Board. Create One! See More Posts on AUPH Message Board See More Message Board Posts

Historical AUPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.925.164.714.961,309,090-0.0896-1.82%
1 Month4.995.414.715.061,309,945-0.1596-3.20%
3 Months7.628.504.715.882,145,447-2.79-36.61%
6 Months7.4710.054.717.252,087,563-2.64-35.34%
1 Year10.6612.434.718.622,165,608-5.83-54.69%
3 Years12.6533.97154.0712.492,939,408-7.82-61.82%
5 Years6.2633.97153.5213.012,510,403-1.43-22.84%

Aurinia Pharmaceuticals Description

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Your Recent History

Delayed Upgrade Clock